Dabomb Protein Biotech (ROCO:6578) Cash-to-Debt : 1.20 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Dabomb Protein Biotech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Dabomb Protein Biotech's cash to debt ratio for the quarter that ended in Mar. 2024 was 1.20.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Dabomb Protein Biotech could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Dabomb Protein Biotech's Cash-to-Debt or its related term are showing as below:

ROCO:6578' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.43 Med: 1.2 Max: 5.62
Current: 1.2

During the past 11 years, Dabomb Protein Biotech's highest Cash to Debt Ratio was 5.62. The lowest was 0.43. And the median was 1.20.

ROCO:6578's Cash-to-Debt is ranked better than
64.24% of 1854 companies
in the Consumer Packaged Goods industry
Industry Median: 0.53 vs ROCO:6578: 1.20

Dabomb Protein Biotech Cash-to-Debt Historical Data

The historical data trend for Dabomb Protein Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Dabomb Protein Biotech Cash-to-Debt Chart

Dabomb Protein Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

1.29

1.07

0.43

0.47

1.03

Dabomb Protein Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															0.48	1.04	0.95	1.03	1.20

Competitive Comparison of Dabomb Protein Biotech's Cash-to-Debt

For the Packaged Foods subindustry, Dabomb Protein Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dabomb Protein Biotech's Cash-to-Debt Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Dabomb Protein Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Dabomb Protein Biotech's Cash-to-Debt falls into.

Dabomb Protein Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Dabomb Protein Biotech's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	429.454	/	(331.665	+	86.337)
	=	1.03

Dabomb Protein Biotech's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	423.778	/	(276.3	+	76.282)
	=	1.20

Dabomb Protein Biotech (ROCO:6578) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Dabomb Protein Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Dabomb Protein Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Dabomb Protein Biotech (ROCO:6578) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Dabomb Protein Biotech Corp (ROCO:6578) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Number 52, Gongye 3rd Road, Annan District, Tainan, TWN, 709

Website

https://www.dabombprotein.com

Dabomb Protein Biotech Corp is a company specializing in antibiotic alternatives, and use postbiotics to boost immune strength and excel in innovative fermentation for improved plant protein utility. Their portfolio of products which include DBT-100 LS and DBT-100 HT , Liqui-TIDE bandage and LACTOTIDES HEALTH A+.

Dabomb Protein Biotech (ROCO:6578) Headlines

No Headlines